Company intelligence / Profile preview

EnFuego Therapeutics, Inc.

Pittsboro, North Carolina, United Statesdirectory.ncbiotech.org ↗

Ownership: Private
Development stage: Preclinical

Overview

EnFuego Therapeutics develops RNAi-based therapeutics to silence oncogenic gene mutations in cancer, focusing on previously "undruggable" targets such as KRAS. Their lead candidate, EFTX‑001, has shown potent silencing of multiple clinically relevant KRAS mutations in preclinical lung cancer models with no detectable toxicity using an FDA-approved lipid nanoparticle delivery system. The company has received SBIR Phase I and II awards and continues to advance its pipeline through preclinical studies.[1][3]

Therapeutic areas: Oncology
Modalities: RNA interference (RNAi)small interfering RNA (siRNA)antisense oligonucleotides[1][6]
Industry: Biotech

Drug pipeline

3 assets

EFTX-G12V

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on EnFuego Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnFuego Therapeutics, Inc..

Explore the full profile